These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24589363)

  • 41. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa.
    Maskew M; Westreich D; Fox MP; Maotoe T; Sanne IM
    J Int AIDS Soc; 2012 Mar; 15(1):13. PubMed ID: 22410312
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
    Sungkanuparph S; Manosuthi W; Kiertiburanakul S; Chantratitra W
    AIDS Patient Care STDS; 2007 Oct; 21(10):711-4. PubMed ID: 17949267
    [No Abstract]   [Full Text] [Related]  

  • 43. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovir disoproxil fumarate in HIV-1-infected children with virologic suppression.
    Saez-Llorens X; Castaño E; Rathore M; Church J; Deville J; Gaur A; Estripeaut D; White K; Arterburn S; Enejosa JV; Cheng AK; Chuck SL; Rhee MS
    Pediatr Infect Dis J; 2015 Apr; 34(4):376-82. PubMed ID: 25760565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection.
    Hazra R; Gafni RI; Maldarelli F; Balis FM; Tullio AN; DeCarlo E; Worrell CJ; Steinberg SM; Flaherty J; Yale K; Kearney BP; Zeichner SL
    Pediatrics; 2005 Dec; 116(6):e846-54. PubMed ID: 16291735
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost and cost-effectiveness of switching from d4T or AZT to a TDF-based first-line regimen in a resource-limited setting in rural Lesotho.
    Jouquet G; Bygrave H; Kranzer K; Ford N; Gadot L; Lee J; Hilderbrand K; Goemaere E; Vlahakis N; Trivino L; Makakole L; Cleary S
    J Acquir Immune Defic Syndr; 2011 Nov; 58(3):e68-74. PubMed ID: 21765366
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipid levels, insulin resistance and cardiovascular risk over 96 weeks of antiretroviral therapy: a randomised controlled trial comparing low-dose stavudine and tenofovir.
    Vos AG; Chersich MF; Klipstein-Grobusch K; Zuithoff P; Moorhouse MA; Lalla-Edward ST; Kambugu A; Kumarasamy N; Grobbee DE; Barth RE; Venter WD
    Retrovirology; 2018 Dec; 15(1):77. PubMed ID: 30547820
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
    Sax PE; Tierney C; Collier AC; Fischl MA; Mollan K; Peeples L; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Koletar SL; Johnson VA; Geiseler PJ; Daar ES;
    N Engl J Med; 2009 Dec; 361(23):2230-40. PubMed ID: 19952143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
    Gerschenson M; Kim C; Berzins B; Taiwo B; Libutti DE; Choi J; Chen D; Weinstein J; Shore J; da Silva B; Belsey E; McComsey GA; Murphy RL
    J Antimicrob Chemother; 2009 Jun; 63(6):1244-50. PubMed ID: 19321503
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses.
    Margot NA; Isaacson E; McGowan I; Cheng A; Miller MD
    J Acquir Immune Defic Syndr; 2003 May; 33(1):15-21. PubMed ID: 12792350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
    J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virological response to initial antiretroviral regimens containing abacavir or tenofovir.
    Bansi L; Sabin C; Gilson R; Gazzard B; Leen C; Anderson J; Dunn D; Hill T; Fisher M; Ainsworth J; Pillay D; Johnson M; Walsh J; Orkin C; Easterbrook P; Gompels M; Phillips A;
    J Infect Dis; 2009 Sep; 200(5):710-4. PubMed ID: 19635022
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tenofovir use and pregnancy among women initiating HAART.
    Maskew M; Westreich D; Firnhaber C; Sanne I
    AIDS; 2012 Nov; 26(18):2393-7. PubMed ID: 22951630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lopinavir/r no longer recommended as a first-line regimen: a comparative effectiveness analysis.
    Potard V; Rey D; Poizot-Martin I; Mokhtari S; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
    J Int AIDS Soc; 2014; 17(1):19070. PubMed ID: 25261780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Spaulding A; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
    Kiage JN; Heimburger DC; Nyirenda CK; Wellons MF; Bagchi S; Chi BH; Koethe JR; Arnett DK; Kabagambe EK
    Lipids Health Dis; 2013 Apr; 12():50. PubMed ID: 23575345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection.
    Gay CL; Mayo AJ; Mfalila CK; Chu H; Barry AC; Kuruc JD; McGee KS; Kerkau M; Sebastian J; Fiscus SA; Margolis DM; Hicks CB; Ferrari G; Eron JJ;
    AIDS; 2011 Apr; 25(7):941-9. PubMed ID: 21487250
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study.
    Esser S; Haberl A; Mulcahy F; Gölz J; Lazzarin A; Teofilo E; Vera J; Körber A; Staszewski S
    Eur J Med Res; 2011 Oct; 16(10):427-36. PubMed ID: 22024421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of the change from Stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy: studies on mitochondrial toxicity and thymic function.
    Rosso R; Nasi M; Di Biagio A; Repetto E; Dentone C; Pinti M; Nemes E; Ferraresi R; Mussini C; Esposito R; Viscoli C; Cossarizza A
    Pediatr Infect Dis J; 2008 Jan; 27(1):17-21. PubMed ID: 18162932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.